bioactive

A collection of 17100 small molecule compounds with validated activity for high throughput screening (HTS), high content screening (HCS), cell induction, and target identification;

It is well-selected from Bioactive compound library Plus (D7800), from which 1-15 compounds with the highest scores (activity value, pharmacological properties, structure-diversity, etc.) were chosen. This library consists of 989 compounds without compro

A collection of 25218 bioactive compounds for high-throughput screening, high-content screening, cell induction and target identification.

A unique collection of 385 bioactive lipids related compounds for high throughput screening (HTS) and high content screening (HCS), including Agonists & Antagonists, Endocannabinoids, Farnesyl geranylgeranyl derivates, HETEs deHETEs, hepoxilins, Polyunsa

A unique collection of 2247 anti-obesity compounds for high throughput and high content screening;

A unique collection of 904 antibacterial bioactive compounds, a powerful tool for antibacterial drug development;

A collection of 499 selected human endogenous metabolites for high throughput and high content screening.

A unique collection of 449 compounds acting on immune-oncology therapeutic targets can be used for high throughput and high content screening；

A unique collection of 1147 monomers from 60 TCM plants, a powerful tool for anti-COVID-19 drug discovery, can be used for HTS and HCS screening；

A unique collection of 685 microbial natural products for high throughput screening (HTS) and high content screening (HCS);

A unique collection of 2938 anti-infective compounds including anti-bacterial, anti-fungi, anti-Human Cytomegalovirus (HCMV), anti-HIV, anti-SARS, anti-influenza, etc;

A unique collection of 3111 plant-sourced compounds that derived from 277 plant species for high throughput screening (HTS) and high content screening (HCS);

A unique collection of 193 bioactive compounds specifically targeting adrenergic receptors, effective tool for screening new drugs or new target identification;

A unique collection of 1133 compounds with confirmed anti-SARS-CoV-2 activity or potential activity and part of them are broad-spectrum antiviral agents；

A unique collection of 1813 reprogramming signaling pathway-related bioactive small molecule compounds for high-throughput, high-content screening.

A unique collection of 317 osteogenesis related compounds for high throughput and high content screening;

419 well-chosen unique anti-parasitic small molecules;

A unique collection of 574 fluorochemicals that can be used for high through-put screening (HTS) and high content screening (HCS);

A unique collection of 153 compounds targeting histaminergic receptor and melatonin receptor for high throughput screening (HTS) and high content screening (HCS) for new drugs;

A unique collection of 1796 annotated bioactive compounds with clear targets, suitable for phenotypic screening；